Non-Alcoholic Fatty Liver Disease

Condition: Non-Alcoholic Fatty Liver Disease  |  Category: Metabolic Health  |  Reviewed by: Brian Lamkin, DO

What Is Non-Alcoholic Fatty Liver Disease?

Non-alcoholic fatty liver disease (NAFLD) is the accumulation of excess fat in liver cells in the absence of significant alcohol consumption. It exists on a spectrum from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH), in which hepatic fat accumulation triggers inflammatory damage, fibrosis, and, if unaddressed, progression to cirrhosis and hepatocellular carcinoma.

The primary driver in the overwhelming majority of NAFLD cases is insulin resistance. Chronically elevated insulin activates hepatic de novo lipogenesis, the metabolic pathway that converts excess dietary carbohydrate, particularly fructose, into triglycerides that are stored in hepatocytes. The liver becomes a fat-producing organ rather than a fat-clearing organ. This mechanism explains why NAFLD is present in up to 80 percent of patients with type 2 diabetes and is tightly correlated with visceral adiposity, dyslipidemia, and the metabolic syndrome cluster.

Why It Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

Conventional hepatology diagnoses NAFLD by ultrasound and monitors liver enzymes. Functional medicine asks what is driving the hepatic fat accumulation and treats the upstream mechanism.

Insulin Resistance and Hepatic De Novo Lipogenesis

The dominant driver. Elevated fasting insulin activates the transcription factor SREBP-1c, which upregulates the enzymes responsible for converting carbohydrate to fat in the liver. This pathway is particularly sensitive to fructose, which bypasses normal glycolytic regulation and is channeled directly into hepatic lipogenesis. HOMA-IR above 1.9 confirms the insulin resistance driving this process.

Visceral Adiposity and Portal Free Fatty Acids

Visceral fat drains directly into the portal circulation, delivering a continuous supply of free fatty acids to the liver. This is why abdominal obesity is more strongly correlated with NAFLD than total body weight. Reducing visceral fat through insulin sensitization and body composition optimization directly reduces hepatic fatty acid delivery.

Gut Dysbiosis and Intestinal Permeability

Gut dysbiosis increases intestinal permeability, allowing lipopolysaccharide (LPS) and other bacterial products to translocate into the portal circulation and activate hepatic Kupffer cells (liver macrophages). This produces hepatic inflammation that compounds the steatosis and accelerates progression from simple fatty liver to NASH. The gut-liver axis is a primary therapeutic target in functional NAFLD management.

Oxidative Stress and Mitochondrial Dysfunction

Hepatic fat accumulation overwhelms mitochondrial beta-oxidation capacity, producing reactive oxygen species that damage hepatocyte membranes, activate stellate cells (the cells responsible for fibrosis), and impair the liver's detoxification pathways. Antioxidant support and mitochondrial optimization are essential components of NAFLD treatment beyond dietary intervention.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

NAFLD evaluation requires metabolic markers that identify the driver of hepatic fat accumulation, not just confirmation that fat is present.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The patient with normal liver enzymes and fatty liver on ultrasound: ALT 28, AST 24 (both within range). Ultrasound shows moderate hepatic steatosis. Told "labs are fine, just lose some weight." Fasting insulin 19, HOMA-IR 4.5, triglyceride/HDL ratio 4.8. The insulin resistance driving hepatic fat was never identified because liver enzymes were normal. Insulin sensitization through dietary modification and berberine produced resolution of steatosis on repeat ultrasound within 6 months.
• The thin patient with fatty liver: BMI 24, not overweight. Fatty liver found incidentally on imaging. Assumed to be an error. Fasting insulin 14, visceral fat on DEXA elevated despite normal BMI. "Lean NAFLD" driven by metabolic dysfunction independent of total body weight. Dietary fructose reduction and insulin sensitization resolved the steatosis.
• The patient told to follow a low-fat diet: Recommended a low-fat, high-carbohydrate diet for fatty liver. Triglycerides increased, fatty liver worsened. The dietary carbohydrate, particularly fructose, was being converted directly to hepatic fat by the same insulin-driven lipogenesis pathway the diet was meant to address. Switching to a low-glycemic, adequate-fat dietary pattern produced immediate triglyceride reduction and progressive hepatic fat clearance.
• NAFLD with concurrent estrogen metabolism impairment: Fatty liver reducing Phase I and Phase II detoxification capacity. Estrogen clearance impaired, producing symptoms of estrogen dominance. Treating the NAFLD restored liver detoxification function and improved the hormonal imbalance concurrently.

Treatment and Optimization Strategy

Dietary and Metabolic Foundation

The highest-impact intervention for NAFLD is dietary: eliminating the substrates that drive hepatic lipogenesis (fructose, refined carbohydrates, seed oils) and reducing the hormonal signal that activates it (insulin). This is not a low-fat diet. It is a low-glycemic, adequate-fat, protein-anchored nutritional strategy that directly addresses the metabolic mechanism.

What Most Doctors Miss

• Normal liver enzymes do not exclude NAFLD: up to 80 percent of patients with ultrasonographic fatty liver have normal ALT. Relying on liver enzymes alone produces massive underdiagnosis.
• Fasting insulin is not measured: the primary metabolic driver of hepatic fat accumulation is not part of standard NAFLD evaluation. Without fasting insulin and HOMA-IR, the mechanism is invisible.
• Low-fat dietary advice worsens NAFLD: replacing dietary fat with carbohydrate increases the substrate for hepatic de novo lipogenesis. NAFLD is a carbohydrate metabolism problem, not a dietary fat problem.
• The gut-liver axis is not assessed: intestinal permeability and LPS translocation from gut dysbiosis are independent drivers of hepatic inflammation that standard hepatology does not evaluate or treat.

When to Seek Medical Care

If you have been diagnosed with fatty liver on imaging, have elevated liver enzymes without a clear explanation, have metabolic syndrome or insulin resistance with abdominal obesity, or have unexplained fatigue with elevated triglycerides, a comprehensive metabolic evaluation of your liver health is warranted.

At The Lamkin Clinic, NAFLD evaluation includes fasting insulin, HOMA-IR, triglyceride/HDL ratio, GGT, hs-CRP, hepatic function markers, and gut health assessment, reviewed together as an integrated metabolic and hepatic profile.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Non-Alcoholic Fatty Liver Disease

At The Lamkin Clinic, NAFLD evaluation begins with comprehensive metabolic testing: fasting insulin, HOMA-IR, triglyceride/HDL ratio, GGT, hs-CRP, and gut health markers. We identify the specific metabolic mechanism driving hepatic fat accumulation and build a treatment protocol targeting insulin reduction, dietary optimization, gut-liver axis restoration, and hepatoprotective support. The goal is metabolic resolution, not monitoring.

Related Conditions

Related Symptoms